Replies to post #612527 on NorthWest Biotherapeutics Inc (NWBO)

[Dr Bala]

And your understanding of the trial design is zilch too.

[SkyLimit2022]

HyGro,

Thanks for reposting your opinions once again, but you are still misinformed and need better sources of credible and verifiable information…

The clinical data in total include data beyond the trial with the ECA, and the ECA included over a thousand well-matched contemporaneous patients.

Regarding the ECA/crossover design and the SAP, please review the video recording of Dr. Ashkan at ASCO 2022 and the JAMA Oncology podcast recording of Dr. Liau. Both recordings are included at the links below.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171254048;

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171254756;

The P3 data were peer reviewed by independent physicians and qualified statisticians—please refer to JAMA Oncology. You might consider researching credible full-context sources to gather reliable information.

The DCVax-L cell-based technology has been under clinical investigation for a significant period of time, and the overall clinical data in total include three trials spanning many years. Safety and efficacy data have been gathered from trials with external controls and trials with placebo controls. The data include DCVax-L as a monotherapy and in combination with other agents.

The interim PD1 combo data are brilliant, and the trial is significant for a number of reasons relating to FDA guidelines and NIH peer-reviewed grant funding.

https://clinicaltrials.gov/ct2/show/NCT04201873

In the combo trial, patients who receive DCVax-L + placebo are being compared to patients who receive DCVax-L + pembrolizumab.

The control arm is receiving DCVax-L. While DCVax-L is not the current SOC, it is highly significant and notable that DCVax-L is being permitted to fill the role of SOC as the best available therapy within this combo study for rGBM. The combo trial also follows the P3 in sequence which in itself validates the findings of the P3 study—the placebo group in the PD1 study would not be receiving DCVax-L today if the preceding P3 trial had not proven its efficacy.

The NIH is the most significant player in this game—If they had any doubt about the P3, the NIH would not continue their support and the FDA would not have permitted the combo trial to commence or continue.

https://clinicaltrials.gov/ct2/show/NCT04201873

The U.S. NIH has supported the DCVax-L platform for years, and the NIH renewed its support in 2022 to continue to fund the development of this technology and to fund research into combination therapies.

NIH-funded DCVax-L research is ongoing at UCLA today.

NIH grants are peer-reviewed and the research that NIH funds is highly scrutinized in advance of the award and also intermittently for the term of the various research projects.



Mr. Newirth is another DCVax-L survivor well surpassing 10 years following a 2012 diagnosis! Congratulations!

https://www.hawaii.edu/news/2017/03/30/newirth-laker-for-a-day/

June 13, 2023 Interview:

https://www.uclahealth.org/news/fda-approval-brain-cancer-alzheimers

Explore Professor Keyoumars Ashkan's passion for neurosurgery and his love for @KingsCollegeNHS below as part of their #BrilliantPeople series🧠👇@KingsNeuro @KingsIoPPN https://t.co/yGKt2681Ie

— King's College London (@KingsCollegeLon) May 25, 2022

https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/

https://www.theguardian.com/science/2022/nov/17/im-just-carrying-on-vaccine-gives-brain-cancer-patient-years-of-extra-life

https://www.braintumourresearch.org/stories/in-hope/in-hope-stories/kat-charles

https://www.uclahealth.org/news/brain-cancer-discovery-clinical-trials

https://www.uclahealth.org/news/ucla-received-590-million-in-nih-funding-second-highest-total-for-academic-medical-centers-in-2020



https://www.fda.gov/science-research/advancing-regulatory-science/fda-nih-joint-leadership-council-charter





September 2023







https://www.cns.org/annualmeeting

[Roman516]

The only issues HG is that the delays for DCVax-L approvals have cost the lives of many cancer patients and that is a clear fact indeed, IMPO.